PR Newswire
25 May 2023, 11:10 GMT+10
Paradigm Biopharma launches clinical trial website to support development program for knee osteoarthritis therapy.
MELBOURNE, Australia, May 25, 2023 /PRNewswire/ -- With the launch of a new website dedicated to their global clinical trials (https://hope4OA.com), Paradigm Biopharmaceuticals Ltd. (Paradigm Biopharma) aims to provide relief to millions of osteoarthritis (OA) sufferers worldwide by developing a new injectable drug.
Almost one in seven American adults has osteoarthritis
OA is a progressive degenerative disease affecting millions worldwide, with estimates reaching nearly half a billion sufferers. Due to their weight bearing role, 70% of all cases affect the hip or the knee.
Ex-Australian Football League (AFL) player Greg 'Diesel' Williams understands all too well how knee OA can have a devastating impact on your life. Greg explains "If you've got OA people really don't understand what we're going through. It's so painful. It's so sore. It's so, so hard to put up with. And it's about time we did something about it."
Dr Philip Bloom is a specialist sports physician with over 20 years' experience and specialist training in treating and managing musculoskeletal injuries and diseases to maximise function. Dr Bloom explains "We see many ex-athletes who have developed osteoarthritis of the knee. They've gone from being super performers to barely being able to go for a decent walk with their family, and it has quite a disabling effect on their whole life."
Paradigm shift for OA treatments
People with OA need alternative therapeutic solutions, as current therapies often don't provide sufficient relief, leaving people in pain and reducing their quality of life.
Dr Philip Bloom comments "Osteoarthritis of the knee is not just an isolated pain in the knee. It has a trickle-down effect on the rest of your life, particularly in regards to losing the ability to be active, which causes obesity, more aches and pains in other joints, and also psychological problems such as depression and anxiety."
Despite the huge need for effective treatments, there are still no registered treatments that can successfully stop or even slow the disease.
Paradigm Biopharma aims to provide hope to OA sufferers by developing a drug to help relieve pain and improve symptoms in people with knee OA.
This drug has been used to treat joint issues in the veterinary space for over 80 years and is registered for use by veterinarians in over 20 countries to treat arthritis in cats, dogs, horses, and even racing camels.
To facilitate current and potential trial participants, Paradigm has launched a new trial website called Hope4OA.com.
Here everyone can discover trial details and find answers to commonly asked questions. If interested, they are invited to complete an online questionnaire to determine their eligibility as a potential trial participant.
The new site hosts helpful explanations and instructional videos on clinical trials as well as providing links to patient support and further information.
To find out more, go to www.hope4oa.com
About Paradigm Biopharmaceuticals Ltd.
Paradigm Biopharmaceuticals Ltd. (ASX:PAR) is a late-stage drug development company driven by a purpose to improve patients' health and quality of life by discovering, developing, and delivering pharmaceutical therapies. Paradigm's current focus is developing injectable (subcutaneous) pentosan polysulfate sodium (iPPS) for the treatment of diseases where inflammation plays a major pathogenic role, indicating a need for the anti-inflammatory and tissue regenerative properties of PPS, such as in osteoarthritis (phase 3) and mucopolysaccharidosis (phase 2).
Get a daily dose of Singapore Star news through our daily email, its complimentary and keeps you fully up to date with world and business news as well.
Publish news of your business, community or sports group, personnel appointments, major event and more by submitting a news release to Singapore Star.
More InformationWASHINGTON D.C.: The Federal Aviation Administration has said that a drone sighting disrupted some flights at Pittsburgh International Airport this ...
PORTLAND, Oregon: A federal trial has begun in Portland, Oregon examining the constitutionality of a stringent gun control law approved ...
PHILADELPHIA, Pennsylvania: Philadelphia Mayor Jim Kenney and members of the city's historical commission have been sued by a group which ...
LANSING, Michigan: Michigan's Department of Natural Resources said by a wildfire in the state has burned through more than 3 ...
ISTANBUL, Turkey: In an interview with Reuters, Willie Walsh, director-general of the International Air Transport Association, (IATA), said airlines are ...
SACRAMENTO, California: Sixteen migrants from Venezuela and Colombia, who had entered the United States through Texas, were transported to California ...
FREMONT, California: Elon Musk's brain implant startup Neuralink, valued at some $2 billion during a private fundraising round two years ...
NEW YORK, New York - U.S. stocks moved higher Thursday as investors and traders took a break from their recent ...
LISBON, Portugal: Carsten Spohr, Chief Executive of Lufthansa, has said that as Portugal's government is still debating whether to sell ...
NEW YORK, New York - U.S. stocks were divided on Wednesday, with the technology and industrial sectors parting ways.Tech stocks ...
HOLLYWOOD, California: More than tripling the debut of its 2018 animated original predecessor, Sony Pictures' "Spider-Man: Across the Spider-Verse" opened ...
PARIS, France: European plane manufacturer Airbus is reported to be close to a record agreement to sell 500 narrow-body jets ...